Search Clinical Trials in the European Union

3-6 months
Visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
301-320 of 331 trials

Momelotinib for Anemia in Low-Risk Myelodysplastic Syndrome

We are studying whether momelotinib can improve red blood cell counts in patients with low-risk myelodysplastic syndrome. The trial also looks at the safety of this treatment.

Myelodysplastic Syndrome3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesPartially RemoteHematologyOncology

Chronic Urticaria: Study of BLU-808

We are testing a new medication, BLU-808, for people with chronic inducible and spontaneous urticaria. The study aims to understand its safety and how well it may help reduce symptoms.

Chronic Urticaria3-6 monthsEfficacy phase (II)Investigational MedicinesAllergologyDermatology

Hodgkin Lymphoma: Ruxolitinib with Brentuximab or Pembrolizumab

We are studying the combination of ruxolitinib with either brentuximab or pembrolizumab for patients with relapsed or refractory classical Hodgkin lymphoma. The goal is to see if this combination improves treatment response and safety.

Recurrent or Refractory Classical Hodgkin Lymphoma3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboStandard MedicinesOncology

Intestinal Failure-Associated Liver Disease: NST-6179 Study

We are testing a new oral medication, NST-6179, for individuals with Intestinal Failure-Associated Liver Disease. The study aims to understand its safety and how it affects liver health.

Intestinal Failure-Associated Liver Disease3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesPartially RemoteGastroenterologyHepatology

Irritable Bowel Syndrome: Saccharomyces boulardii CNCM I-745

We are studying whether a probiotic can help adults with non-constipated IBS feel better and improve their quality of life compared to a placebo.

Non-constipated Irritable Bowel Syndrome3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesCost ReimbursementPartially RemoteGastroenterology

Multiple Sclerosis: THC/CBD Oral Solution

We are studying an oral solution of THC and CBD for people with multiple sclerosis to see if it helps relieve chronic pain and improve other symptoms. This trial compares the treatment to a placebo to assess its effects.

Chronic Neuropathic Pain3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesInternal MedicineNeurology

Generalized Myasthenia Gravis: Descartes-08 Treatment

We are studying a new treatment called Descartes-08 for people with generalized myasthenia gravis. The trial aims to see if it helps improve daily activities and muscle strength compared to a placebo.

Generalized Myasthenia Gravis3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesNeurology

Bone Health: Everolimus and Exercise for Postmenopausal Women

We are studying if a combination of a medication and resistance training can improve bone formation in healthy postmenopausal women. This research may help in understanding better ways to support bone health.

Healthy Elderly Women3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementGynecology and ObstetricsOrthopedics and Traumatology

Neurogenic Inflammation: TRPA1 Activation Study

We are investigating how a specific compound affects inflammation in people with conditions related to nerve pain. This research may help us understand better ways to manage pain and inflammation.

Healthy Participants3-6 monthsSafety phase (I)

Platysma Prominence: NT 201 Treatment Study

We are investigating whether NT 201 can safely reduce moderate to severe platysma prominence in adults compared to a placebo. This study aims to find out if this treatment can improve appearance and confidence.

Moderate to Severe Platysma Prominence3-6 monthsConfirmation phase (III)Post-Trial Drug AccessStandard MedicinesDermatology

Alzheimer's Disease: KarXT + KarX-EC Treatment

We are studying a new combination treatment for agitation in people with Alzheimer's disease. The goal is to see if it can reduce agitation symptoms better than a placebo.

Alzheimer's Disease Agitation3-6 monthsConfirmation phase (III)11-15 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurologyPsychiatry

ELA026 for Secondary Hemophagocytic Lymphohistiocytosis (sHLH)

We are studying the effects of ELA026 on survival in patients with sHLH triggered by lymphoma. This trial will help us understand how well this treatment works and its safety.

Secondary Hemophagocytic Lymphohistiocytosis (sHLH)3-6 monthsEfficacy phase (II)Confirmation phase (III)>20 visitsNo PlaceboInvestigational MedicinesPartially RemoteHematologyInfectious Diseases

Dengue Vaccine Qdenga: Antibody Response Study

We are examining how the Qdenga vaccine affects antibody levels for other flavivirus infections in Swedish travelers. This study aims to see if vaccination leads to higher antibody levels that could interfere with diagnostic tests.

Healthy Participants3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesAllergologyHematologyInfectious Diseases

Idiopathic Hypersomnia: ALKS 2680 Study

We are evaluating a new medication, ALKS 2680, for individuals with Idiopathic Hypersomnia to see if it helps reduce excessive daytime sleepiness and is safe to use.

Idiopathic Hypersomnia3-6 monthsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteInternal MedicineNeurology

Graves' Disease: Rilzabrutinib Study

We are investigating whether rilzabrutinib can help reduce thyroid activity in adults with Graves' disease. The study also aims to evaluate the safety of this new treatment.

Graves' Disease3-6 monthsEfficacy phase (II)11-15 visitsNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyInternal Medicine

Non-Small Cell Lung Cancer: RMC-9805 and RMC-6236 Study

We are studying a new treatment combination for patients with RAS G12D-mutant non-small cell lung cancer. The trial will evaluate the safety and effectiveness of these drugs alongside other anticancer therapies.

Non-small Cell Lung Cancer3-6 monthsEfficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesCost ReimbursementOncologyPulmonology

Chronic Subdural Hematoma: Timing of Anticoagulation

We are studying whether starting blood-thinning medication early or later helps patients with atrial fibrillation recover better after surgery for chronic subdural hematoma. This research looks at potential risks and overall health outcomes.

Chronic Subdural HematomaAtrial Fibrillation3-6 monthsEfficacy phase (II)Confirmation phase (III)No PlaceboStandard MedicinesPartially RemoteCardiologyInternal MedicineNeurology

Lactose Intolerance: Gaxilose Oral Treatment

We are testing a new oral treatment called Gaxilose in healthy adults to see if it improves the body's ability to digest lactose. This study aims to understand its potential benefits for those with lactose intolerance.

Lactose Intolerance3-6 monthsSafety phase (I)Gastroenterology

Cerebrolysin for Recovery After Ischemic Stroke

We are studying whether Cerebrolysin can improve upper limb function and overall recovery in patients after an ischemic stroke. Participants will be compared to those receiving a placebo to assess various health outcomes.

Ischaemic Stroke3-6 monthsConfirmation phase (III)≤5 visitsStandard MedicinesNeurology

Atrial Fibrillation: AP31969 Medication Study

We are testing a new medication, AP31969, for people with atrial fibrillation to see if it helps control their heart rhythm and improve their quality of life. The study will also evaluate the safety of this treatment.

Atrial Fibrillation3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCardiologyInternal Medicine